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Summary A 33-year-old woman underwent unrelated cord blood transplantation (U-CBT) for
myelodysplastic syndrome (MDS)-related secondary AML. She showed impressive increases
in the number of CD19
+ B cells in bone marrow and CD19
+27
)IgD
+ B cells in peripheral
blood from about 1 month to 3 months after U-CBT. The serum level of IL-6 temporarily
increased after transplantation, and this increase seemed to be correlated with the
expansion of CD19
+ B cells. Although, compared with BMT, little is known about the
kinetics of hematological and immunological reconstitution in U-CBT, there was initial
B-cell recovery after CBT as some described. This B cell recovery may be associated with a
high number of B-cell precursors present in cord blood (CB). The phenomenon of naı ¨ve B
lymphocyte expansion that we found might be associated with a high number of B-cell
precursors present in CB.
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Case history
A 33-year-old woman with myelodysplastic syndrome
(MDS)-related secondary acute myelogenous leukemia
(AML) underwent unrelated cord blood transplantation
(U-CBT) from HLA 1-antigen (DRB1) mismatched donor in
April 2003. The conditioning regimen consisted of total
body irradiation (TBI, 12 Gy) on days )9, )8, and )7, and
cytarabine (Ara-C) at 3 g/m
2 every 12 h on days )6 and
)5, and cyclophosphamide (CY) at 60 mg/kg once daily
on days )4 and )3. FK 506 and short-term methotrexate
(MTX) were used for graft-versus-host disease (GVHD)
prophylaxis. The number of infused nucleated cells and
CD34
+ cells were 3.0 · 10
7/kg and 2.8 · 10
4/kg respect-
ively. Neutrophil and platelet engraftment was achieved
on day 18 and day 28 respectively. We examined donor-
type chimerism in the peripheral blood (PB) mononuclear
cells by the procedure reported in detail previously
Received 23 December 2005; accepted for publication 14 June 2006
Correspondence: Dr Tomomi Toubai, Hematology and Oncology,
Hokkaido University Graduate School of Medicine, N15W7, Kita-ku,
Sapporo, 060-8638, Japan. Tel: +81 11 706 7214; Fax:
+81 11 706 7823; E-mail: ttoubai@hkg.odn.ne.jp
Re-use of this article is permitted in accordance with the Creative
Commons Deed, Attribution 2.5, which does not permit commercial
exploitation.
Clin. Lab. Haem. doi: 10.1111/j.1365-2257.2006.00809.x
2006, 28, 351–354
  2006 The Authors
Journal compilation   2006 Blackwell Publishing Ltd
351(Tsutsumi et al., 2002), complete donor type revealed on
day 28. Acute GVHD was observed about 2 weeks after
transplantation (skin, stage 2; gut, stage 3; overall, grade
III), but the symptoms gradually subsided after predniso-
lone administration at a single dose of 1 mg/kg. FK506
therapy was stopped on day 31 when GVHD symptoms
had disappeared. The patient showed an impressive
increase in the number of CD19
+ B cells in bone marrow
(BM) and PB starting approximately 1 month after U-CBT
(Figure 1a,b). Bone marrow aspirate on day 62 showed
various types of blastic-appearing lymphocytes (47.4%)
with a high nuclear/cytoplasmic ratio and a ﬁne nucleo-
reticulum (Figure 2). These lymphocytes also had mark-
edly reduced granulation. These lymphocytes also
expressed CD20 antigen (data unshown). This increase
was not apparently related to a defective control of
Epstein–Barr virus (EBV) infection or reactivation, which
was conﬁrmed by the negative results of PCR and
Southern blot analysis on day 62. EBV serological
examination before U-CBT revealed viral capsid antigen
(VCA)-IgG 40·, VCA-IgM < 10·, VCA-IgA < 10·, early
antigen for DR components (EADR)-IgG < 10·, EADR-
IgA < 10· and EBV nuclear antigen (EBNA) 10·. More-
over, EBV serological examination on day 62 after U-CBT
revealed VCA-IgG 160·, VCA-IgM < 10·, VCA-
IgA < 10·, EADR-IgG < 10·, EADR-IgA < 10· and
EBNA 40·. The patient remained afebrile, and there was
no newly emerged lymphadenopathy. Cytomegalo virus
(CMV) antigenemia was negative at all times after the
transplantation, and there was no indication of any
bacterial infection. Results of serological examinations of
Parvovirus B19 and Herpes simplex virus (HSV) were
negative, and Human papiloma virus- 6 (HHV-6) was not
examined. Immunoglobulin heavy chain (IgH) clonality
analysis showed negative rearrangement. To evaluate the
correlation between immunological reconstitution and
circulating serum cytokines, serum levels of interleukin-2
(IL-2), interleukin-6 (IL-6), interleukin-10 (IL-10) and
interferon-c (IFN-c) were also examined. We found that
the serum level of IL-6 temporarily increased after
transplantation and that this increase correlated with
the expansion of CD19
+ B cells (Figure 1b). However, IL-2,
IL-10 and IFN-c were not detected. The CD19
+ B cells
were analyzed in detail using anti CD27 Ab and anti IgD
(Figure 3a,b). IgD
+ CD27
) cells (naı ¨ve B cells) in the
CD19
+ B cells increased in BM and PB. Results of other
routine examinations were unremarkable except for the
presence a relatively high percentage of lymphocytes in
PB. Sequential analysis of chimerism status of CD19
+cells
was performed, and complete donor chimerism persisted
after transplantation. Taking all of these facts into
Figure 1. Levels of WBCs, peripheral lymphocytes, peripheral
CD19
+ lymphocytes, and CD20
+ lymphocytes after U-CBT (a)
and levels of CD19
+ lymphocytes and CD20
+ lymphocytes in BM
and serum IL-6 after U-CBT (b). CD19
+ and CD20
+ lymphocyte
counts peaked on day 63.
Figure 2. Bone marrow smear. (May-Gimza stain ·1000). Bone
marrow aspirate on day 62 shows various types of blastic-
appearing lymphocytes with a high nuclear/cytoplasmic ratio
and a ﬁne nucleoreticulum. These lymphocytes also had mark-
edly reduced granulation.
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malignant state that resulted from a peculiar immunologic
reconstitution after U-CBT, and we just followed up the
patient carefully. The number of CD19
+ B cells in BM and
PB gradually normalized afterwards. Further, we observed
that CD4
+CD8
+ cell ratios in PB were 0.42, 1.17 and 1.29
at 1, 3 and 4 months respectively. Absolute counts of
CD3
+ cells, CD4
+ cells and CD8
+ cells of >500/ll were
achieved at 3, 4 and 4 months respectively. Immune
reconstitution in these lymphocyte subsets was earlier
than that reported by Giraud et al. (2000).
Discussion
An increase in lymphocytes in PB approximately
2 months after U-CBT has been described in a few reports
(Locatelli et al., 1996; Elhasid et al., 2000; Moretta et al.,
2001) but there was no mention of lymphocytes in BM in
these reports. It has been reported that CD19
+ B cells
showed prompt recovery after CBT (Giraud et al., 2000,
Niehues et al., 2001; Inoue et al., 2003). Giraud et al.
(2000) found that B cells the recovered early and at 6 and
9 months they constituted the predominant lymphocyte
subset. They also found that the absolute CD19
+ B cell
number was elevated at 12 months in all of their child
patients except for the one with severe chronic GVHD after
unrelated CBT. Inoue et al. (2003) compared immune
reconstitution after allogeneic CBT and CD34
+ stem cell
transplantation (CD34
) SCT) with that after BMT in
children and found that both the number and percentage
of CD19
+ B cells were higher after CBT. Moreover, B cell
recovery may be associated with a high number of B-cell
precursors present in CB (Arakawa-Hoyt et al., 1999;
Knutsen & Wall, 2000). However, there were no data of
subpopulations of B cells after CBT. We analyzed the B
lymphocytes of the adult patient after U-CBT using three
subpopulations on the basis CD27 and IgD expression.
Klein, Rajewsky and Kuppers (1998) reported that PB of
healthy donors showed considerable variation in the
percentages of the B-cell subsets, with 29–65%
IgD
+CD27
), 6.5–22% IgD
+CD27
+ and 13–43%
IgD
)CD27
+ B cells. Although the percentages of B-cell
subsets in BM were unclear, our case showed a clear
increase in naı ¨ve B cells. It has been hypothesized that this
striking expansion of B cells is due to the absence of long-
term memory B cells; long-term memory B cells are
usually found in adult BM, whereas only immature naı ¨ve
B lymphocytes are found in cord blood (Locatelli et al.,
1996). It is conceivable that neonatal B lymphocytes or
their precursors present in cord blood maintain an efﬁcient
self-renewal capacity even after being transplanted into an
allogeneic host.
We studied serum levels of IL-2, IL-6, IL-10 and IFN-c to
examine the relationship between immunological recon-
stitution and circulating serum cytokines. IL-6 was the
only cytokine that increased after U-CBT, and its increase
was correlated with the expansion of CD19
+ B cells
(Figure 2-b). In regard to the increases of serum IL-6 level
in allogeneic BMT, this phenomenon was observed early
after the transplantation and appeared to be one of the
causative cytokines for GVHD induction (Imamura et al.,
1994). We cannot demonstrate a clear cause-and-effect
relationship between the increases in serum level of IL-6
and number of CD19
+ B cells, however, this correlation is
interesting and further studies are expected.
In conclusion, an impressive increase in CD19
+ B cells,
especially naı ¨ve B cells, in BM and PB starting about
1 month after U-CBT was found, and this phenomenon of
naı ¨ve B lymphocyte expansion might be associated with a
high number of B-cell precursors present in CB.
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